Nivolumab Induces Sustained Liver Injury in a Patient with Malignant Melanoma

A 42-year-old man was diagnosed with cStage IIIb malignant melanoma and underwent resection. After interferon-beta therapy, 18-fluorodeoxyglucose-positron emission tomography/computed tomography ((18)F-FDG PET/CT) showed multiple lung metastases, and he received nivolumab (2 mg/kg) every 3 weeks, re...

Descripción completa

Detalles Bibliográficos
Autores principales: Matsubara, Tokuhiro, Nishida, Tsutomu, Higaki, Yu, Tomita, Ryo, Shimakoshi, Hiromi, Shimoda, Akiyoshi, Osugi, Naoto, Sugimoto, Aya, Takahashi, Kei, Nakamatsu, Dai, Mukai, Kaori, Yamamoto, Masashi, Fukui, Koji, Adachi, Shiro, Inada, Masami
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Japanese Society of Internal Medicine 2018
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6047996/
https://www.ncbi.nlm.nih.gov/pubmed/29434164
http://dx.doi.org/10.2169/internalmedicine.9851-17
Descripción
Sumario:A 42-year-old man was diagnosed with cStage IIIb malignant melanoma and underwent resection. After interferon-beta therapy, 18-fluorodeoxyglucose-positron emission tomography/computed tomography ((18)F-FDG PET/CT) showed multiple lung metastases, and he received nivolumab (2 mg/kg) every 3 weeks, resulting in a total of 17 cycles. After treatment, (18)F-FDG PET/CT showed a significant decrease in the size of the metastases, but he had a Grade 4 alanine aminotransferase (ALT) elevation. Liver histology revealed drug-induced liver damage. Therefore, we performed steroid half-pulse therapy followed by oral methylprednisolone, but his ALT level did not completely recover to the normal range even after five months. We herein report a case with specific, sustained liver injury induced by nivolumab as an immune-related adverse events.

Ejemplares similares